Inmune Bio (INMB) Operating Margin (2021 - 2025)
Inmune Bio (INMB) has disclosed Operating Margin for 5 consecutive years, with 19810.0% as the latest value for Q1 2025.
- Quarterly Operating Margin rose 5888286.0% to 19810.0% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 94766.0% through Dec 2025, up 20976971.0% year-over-year, with the annual reading at 94766.0% for FY2025, 20976971.0% up from the prior year.
- Operating Margin hit 19810.0% in Q1 2025 for Inmune Bio, up from 78692.86% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 3974.23% in Q1 2022 to a low of 113700.0% in Q1 2021.
- Historically, Operating Margin has averaged 32314.32% across 5 years, with a median of 19810.0% in 2025.
- Biggest five-year swings in Operating Margin: skyrocketed 10972577bps in 2022 and later tumbled -6179023bps in 2024.
- Year by year, Operating Margin stood at 5539.88% in 2021, then decreased by -5bps to 5816.49% in 2022, then plummeted by -414bps to 29925.0% in 2023, then crashed by -163bps to 78692.86% in 2024, then skyrocketed by 75bps to 19810.0% in 2025.
- Business Quant data shows Operating Margin for INMB at 19810.0% in Q1 2025, 78692.86% in Q1 2024, and 29925.0% in Q4 2023.